Actinium Pharmaceuticals’ (ATNM) “Buy” Rating Reaffirmed at HC Wainwright

Actinium Pharmaceuticals (NYSE:ATNM)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued on Friday, Benzinga reports. They presently have a $50.00 price target on the stock.

Actinium Pharmaceuticals Stock Performance

Actinium Pharmaceuticals stock opened at $7.90 on Friday. Actinium Pharmaceuticals has a 12-month low of $4.00 and a 12-month high of $10.24.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.